Albendazole Important Safety Information
Benzimidazoles were originally developed as plant fungicides and later as veterinary and human anthelmintics. The family of benzimidazoles with anthelmintic activity includes thiazolyl benzimidazoles and benzimidazole carbamates. The benzimidazoles show a broad spectrum of activity against helminth parasites. Well known benzimidazoles with activity against helminths are for example thiabendazole; cambendazole; and benzimidazole carbamates, such as parbendazole (U.S. Pat. No. 3,480,642), mebendazole (U.S. Pat. No. 3,657,267), flubendazole (U.S. Pat. No. 3,657,267), fenbendazole (U.S. Pat. No. 3,954,791), oxfendazole (U.S. Pat. No. 3,929,821), oxibendazole (U.S. Pat. No. 3,574,845), albendazole (U.S. Pat. No. 3,915,986), ricobendazole ( albendazole sulfoxide) (U.S. Pat. No. 3,915,986) and luxabendazole (U.S. Pat. No. 4,639,463), all of which differ in the substituents on the parent benzimidazole nucleus.
Benzimidazoles are believed to owe their activity to the fact that they block the polymerization of beta-tubulin into microtubules. This affects the transport functions of cells within the parasite and ultimately kills the parasite.
Phenylguanidine prodrugs that are metabolically transformed into anthelmintic benzimidazoles have also been developed. Febantel (U.S. Pat. No. 3,993,682), for example, is a prodrug that is converted into fenbendazole, and netobimin (U.S. Pat. No. 4,406,893) yields albendazole. Albendazole is an anthelmintic medication used in the treatment of infections of the body caused by tapeworms. The medication works by preventing newly hatched worms from growing and multiplying from within the body. As with most anthelmintic medications, there are certain side effects associated with treatment.
Efforts regarding benzimidazole prodrugs were undertaken in the context of the use of the benzimidazoles in the combat of systemic infections, for example with the larval stage of the cestodes, Echinococcus multicularis and E. granulosis . In these cases plasma and tissue levels of the drugs are important since, in order to act systemically, the benzimidazoles have to be taken up into the bloodstream.
Certain albendazole prodrugs are described by Hernández-Luis et al. in Bioorganic & Medicinal Chemistry Letters, 11, 1359-1362, 2001. Hernández-Luis et al. attempted to enhance the solubility of albendazole by synthesizing three N-acyl and two N-alkoxycarbonyl derivatives. These derivatives were developed mainly in the context of the use of albendazole products for some tissue dwelling infestations such as trichinellosis, hydrated disease (echinococcsis) and neurocysticerosis, where high doses and long treatment are required due to the poor solubility and absorption of albendazole. Before taking Albendazole, tell your doctor if you have ever suffered from liver disease or any type of liver condition as you may not be able to use this medication. This medication is classified as FDA pregnancy category C and it may cause harm to an unborn baby. It is also unknown whether or not the drug is secreted into breast milk, and it is recommended to use extreme caution if you are nursing while using this medication. Also, consult with your doctor if you have ever had an allergic reaction to any type of food or medication before using this drug.
Benzimidazoles are believed to owe their activity to the fact that they block the polymerization of beta-tubulin into microtubules. This affects the transport functions of cells within the parasite and ultimately kills the parasite.
Phenylguanidine prodrugs that are metabolically transformed into anthelmintic benzimidazoles have also been developed. Febantel (U.S. Pat. No. 3,993,682), for example, is a prodrug that is converted into fenbendazole, and netobimin (U.S. Pat. No. 4,406,893) yields albendazole. Albendazole is an anthelmintic medication used in the treatment of infections of the body caused by tapeworms. The medication works by preventing newly hatched worms from growing and multiplying from within the body. As with most anthelmintic medications, there are certain side effects associated with treatment.
Efforts regarding benzimidazole prodrugs were undertaken in the context of the use of the benzimidazoles in the combat of systemic infections, for example with the larval stage of the cestodes, Echinococcus multicularis and E. granulosis . In these cases plasma and tissue levels of the drugs are important since, in order to act systemically, the benzimidazoles have to be taken up into the bloodstream.
Certain albendazole prodrugs are described by Hernández-Luis et al. in Bioorganic & Medicinal Chemistry Letters, 11, 1359-1362, 2001. Hernández-Luis et al. attempted to enhance the solubility of albendazole by synthesizing three N-acyl and two N-alkoxycarbonyl derivatives. These derivatives were developed mainly in the context of the use of albendazole products for some tissue dwelling infestations such as trichinellosis, hydrated disease (echinococcsis) and neurocysticerosis, where high doses and long treatment are required due to the poor solubility and absorption of albendazole. Before taking Albendazole, tell your doctor if you have ever suffered from liver disease or any type of liver condition as you may not be able to use this medication. This medication is classified as FDA pregnancy category C and it may cause harm to an unborn baby. It is also unknown whether or not the drug is secreted into breast milk, and it is recommended to use extreme caution if you are nursing while using this medication. Also, consult with your doctor if you have ever had an allergic reaction to any type of food or medication before using this drug.